

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 July 2018 (26.07.2018)



(10) International Publication Number
WO 2018/134213 A1

(51) International Patent Classification:

C07D 403/04 (2006.01) *A61P 17/14* (2006.01)
C07D 403/14 (2006.01) *A61P 37/00* (2006.01)
A61K 31/506 (2006.01)

(21) International Application Number:

PCT/EP2018/051038

(22) International Filing Date:

16 January 2018 (16.01.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/447,057 17 January 2017 (17.01.2017) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85 Södertälje (SE).

(72) Inventors: **NILSSON, Karl, Magnus**; AstraZeneca, 431 83 Mölndal (SE). **ÅSTRAND, Annika, Birgitta, Margareta**; AstraZeneca, 431 83 Mölndal (SE). **BERGGREN, Anna, Ingrid, Kristina**; AstraZeneca, 431 83 Mölndal (SE). **JOHANSSON, Johan, R.**; AstraZeneca, 431 83 Mölndal (SE). **LEPISTÖ, Matti, Juhani**; AstraZeneca, 431 83 Mölndal (SE). **KAWATKAR, Sameer, Pralhad**; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilm-

ington, DE 19803 (US). **SU, Qibin**; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE 19803 (US). **KETTLE, Jason, Grant**; 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB).

(74) Agent: **ASTRAZENECA**; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: JAK1 SELECTIVE INHIBITORS





FIG. 3



(57) Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R₁-R₈ have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*